We can make gout management more successful now

被引:48
作者
Becker, Michael A. [1 ]
Chohan, Saima [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Dept Med, Rheumatol Sect, Chicago, IL 60637 USA
关键词
diagnosis and management; evidence-based management guidelines; gout; lifestyle and pharmacological interventions; urate crystals; urate-lowering agents;
D O I
10.1097/BOR.0b013e3282f54d03
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Purpose of review The purpose of this editorial review is to identify and comment on factors contributing to the current less-than-optimal state of gout management and to emphasize immediate opportunities to improve management practices affecting many patients with gout. Recent findings Numerous publications document deficits in the current management and clinical outcomes of gout despite detailed understanding of the pathogenesis and pathophysiology of the disorder, the ability to establish the diagnosis with certainty, and the likely effectiveness, for most patients, of available lifestyle and pharmacological interventions. Among impediments to successful gout management are diagnostic inaccuracy; a paucity of validated management recommendations to guide care providers; incomplete patient education about gout and the aims and modalities of management; suboptimal patient adherence, even to demonstrably effective therapeutic recommendations; comorbidities and drug interferences that complicate treatment of gout; patient groups at special risk for progression to chronic tophaceous gout; and limited urate-lowering alternatives. Summary Recent publication of evidence-based recommendations for the diagnosis and management of gout and the impending availability of new urate-lowering agents suggest that this is an opportune time to initiate professional and patient education efforts toward improved management of this increasingly common disorder.
引用
收藏
页码:167 / 172
页数:6
相关论文
共 44 条
[1]
ALLOPURINOL HYPERSENSITIVITY SYNDROME - A REVIEW [J].
ARELLANO, F ;
SACRISTAN, JA .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (03) :337-343
[2]
Arromdee E, 2002, J RHEUMATOL, V29, P2403
[3]
BAETHGE BA, 1993, J RHEUMATOL, V20, P718
[4]
Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].
Becker, MA ;
Schumacher, HR ;
Wortmann, RL ;
MacDonald, PA ;
Eustace, D ;
Palo, WA ;
Streit, J ;
Joseph-Ridge, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461
[5]
Becker MA, 2004, NUCLEOS NUCLEOT, V23, P35
[6]
Hyperuricemia and associated diseases [J].
Becker, Michael A. ;
Jolly, Meenakshi .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2006, 32 (02) :275-+
[7]
Borstad GC, 2004, J RHEUMATOL, V31, P2429
[8]
Trends in the manifestations of gout in Taiwan [J].
Chen, SY ;
Chen, CL ;
Shen, ML ;
Kamatani, N .
RHEUMATOLOGY, 2003, 42 (12) :1529-1533
[9]
Obesity, weight change, hypertension, diuretic use, and risk of gout in men - The health professionals follow-up study [J].
Choi, HK ;
Atkinson, K ;
Karlson, EW ;
Curhan, G .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (07) :742-748
[10]
Independent impact of gout on mortality and risk for coronary heart disease [J].
Choi, Hyon K. ;
Curhan, Gary .
CIRCULATION, 2007, 116 (08) :894-900